Cardiac matrix: A clue for future therapy
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the heart, miRNAs are involved both in cardiogenesis (14, 15) and in disease including: diabetic cardiomyopathy, hypertrophy, ischemia, and electrical remodeling (16-22).”
In the citing paper
“Recent developmentsinboththerapeutic inhibition and enhancement of miRNA function have demonstrated great promise for counteracting cardiac diseases (22, 23).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Substrate Elasticity Regulates Skeletal Muscle Stem Cell Self-Renewal in Culture
Gilbert, P. M., Havenstrite, K. L., Magnusson, K. E. G., Sacco, A., Leonardi, N. A., Kraft, P., Nguyen, N. K., Thrun, S., Lutolf, M. P., & Blau, H. M. (2010) · Science · doi:10.1126/science.1191035 · Cited by 1,587 · cited 4×
“It is documented that embryonic cardiomyocytes beat best on a matrix with heart like elasticity [2].”
BackgroundInfluentialEarly induction of matrix metalloproteinase-9 transduces signaling in human heart end stage failure
Moshal, K. S., Tyagi, N., Moss, V., Henderson, B., Steed, M., Ovechkin, A., Aru, G. M., & Tyagi, S. C. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00501.x · Cited by 61
Self-citationFelkin, L. E., Birks, E. J., George, R., Wong, S., Khaghani, A., Yacoub, M. H., & Barton, P. J. R. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.09.006 · Cited by 59
Research works printed but not linked: 73
- Engler, 2006, Matrix elasticity directs stem cell lineage specification, Cell, 126, 677, 10.1016/j.cell.2006.06.044 · DOI · Paper page
- Kajstura, 2008, The human heart: a self-renewing organ, Clin. Transl. Sci., 1, 80, 10.1111/j.1752-8062.2008.00030.x · DOI
- Bolli, 2011, Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial, Lancet, 378, 1847, 10.1016/S0140-6736(11)61590-0 · DOI · Paper page
- Hu, 2011, Novel microRNA prosurvival cocktail for improving engraftment and function of cardiac progenitor cell transplantation, Circulation, 124, S27, 10.1161/CIRCULATIONAHA.111.017954 · DOI · Paper page
- Tyagi, 2011, Synergy of microRNA and stem cell: a novel therapeutic approach for diabetes mellitus and cardiovascular diseases, Curr. Diabetes Rev., 7, 367, 10.2174/157339911797579179 · DOI
- Mishra, 2010, MMP-9 gene ablation and TIMP-4 mitigate PAR-1-mediated cardiomyocyte dysfunction: a plausible role of dicer and miRNA, Cell Biochem. Biophys., 57, 67, 10.1007/s12013-010-9084-1 · doi:10.1007/s12013-010-9084-1
- Mishra, 2012, Ablation of MMP9 induces survival and differentiation of cardiac stem cells into cardiomyocytes in the heart of diabetics: a role of extracellular matrix, Can. J. Physiol. Pharmacol., 90, 353, 10.1139/y11-131 · DOI
- Mishra, 2010, Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol, Cardiovasc. Diabetol., 9, 49, 10.1186/1475-2840-9-49 · DOI
- Tyagi, 1993, Myocardial matrix metalloproteinase(s): localization and activation, Mol. Cell. Biochem., 126, 49, 10.1007/BF01772207 · DOI
- Dhanaraj, 1996, X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily, Structure, 4, 375, 10.1016/S0969-2126(96)00043-3 · DOI
- Bernstein, 1998, Data-based approach for developing a physical activity frequency questionnaire, Am. J. Epidemiol., 147, 147, 10.1093/oxfordjournals.aje.a009427 · DOI · Paper page
- Moshal, 2008, Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia, Am. J. Physiol. Heart Circ. Physiol., 295, H890, 10.1152/ajpheart.00099.2008 · DOI
- Moshal, 2008, Mitochondrial MMP activation, dysfunction and arrhythmogenesis in hyperhomocysteinemia, Curr. Vasc. Pharmacol., 6, 84, 10.2174/157016108783955301 · doi:10.2174/157016108783955301
- Givvimani, 2010, MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure, Arch. Physiol. Biochem., 116, 63, 10.3109/13813451003652997 · DOI
- Ma, 2004, Brg-1 is required for maximal transcription of the human matrix metalloproteinase-2 gene, J. Biol. Chem., 279, 46326, 10.1074/jbc.M405438200 · DOI
- Qin, 1999, The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells, J. Biol. Chem., 274, 29130, 10.1074/jbc.274.41.29130 · DOI · Paper page
- Gutierrez, 2008, Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection, J. Infect. Dis., 197, 1468, 10.1086/587487 · DOI
- Wang, 2006, Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility, Cardiovasc. Res., 69, 688, 10.1016/j.cardiores.2005.08.023 · DOI
- Li, 1996, Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions, Am. J. Pathol., 148, 121
- Lovett, 2012, A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity, PLoS One, 7, e34177, 10.1371/journal.pone.0034177 · DOI
- Libby, 2000, Matrix matters, Circulation, 102, 1874, 10.1161/01.CIR.102.16.1874 · DOI · Paper page
- Libby, 2001, Current concepts of the pathogenesis of the acute coronary syndromes, Circulation, 104, 365, 10.1161/01.CIR.104.3.365 · DOI · Paper page
- Spoto, 2012, Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure, Nephrol. Dial. Transplant., 27, 2440, 10.1093/ndt/gfr710 · doi:10.1093/ndt/gfr710
- Seo, 2011, An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo, Peptides, 32, 1840, 10.1016/j.peptides.2011.08.010 · DOI
- Seo, 2003, TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism, Cell, 114, 171, 10.1016/S0092-8674(03)00551-8 · DOI · Paper page
- Kallio, 2011, TIMP-3 promotes apoptosis in nonadherent small cell lung carcinoma cells lacking functional death receptor pathway, Int. J. Cancer, 128, 991, 10.1002/ijc.25404 · DOI
- Finan, 2006, In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2, Lung Cancer, 53, 273, 10.1016/j.lungcan.2006.06.006 · DOI
- Koskivirta, 2010, Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload, J. Biol. Chem., 285, 24487, 10.1074/jbc.M110.136820 · DOI · Paper page
- Ahmed, 2006, Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease, Circulation, 113, 2089, 10.1161/CIRCULATIONAHA.105.573865 · DOI · Paper page
- Spinale, 2013, Membrane-associated matrix proteolysis and heart failure, Circ. Res., 112, 195, 10.1161/CIRCRESAHA.112.266882 · DOI · Paper page
- Peterson, 2001, Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure, Circulation, 103, 2303, 10.1161/01.CIR.103.18.2303 · DOI · Paper page
- Rizzi, 2010, Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension, J. Card. Fail., 16, 599, 10.1016/j.cardfail.2010.02.005 · DOI
- Rizzi, 2013, Temporal changes in cardiac matrix metalloproteinase activity, oxidative stress, and TGF-beta in renovascular hypertension-induced cardiac hypertrophy, Exp. Mol. Pathol., 94, 1, 10.1016/j.yexmp.2012.10.010 · DOI
- Ferraz, 2013, Recombinant human matrix metalloproteinase-2 impairs cardiovascular beta-adrenergic responses, Basic Clin. Pharmacol. Toxicol., 112, 103, 10.1111/bcpt.12001 · DOI
- Phatharajaree, 2007, Matrix metalloproteinases and myocardial infarction, Can. J. Cardiol., 23, 727, 10.1016/S0828-282X(07)70818-8 · DOI
- Neto-Neves, 2013, Matrix metalloproteinases as drug targets in acute pulmonary embolism, Curr. Drug Targets, 14, 344
- Neto-Neves, 2011, Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism, Crit. Care Med., 39, 349, 10.1097/CCM.0b013e3181fa3dfe · DOI
- Sousa-Santos, 2012, Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism, Naunyn Schmiedebergs Arch. Pharmacol., 385, 685, 10.1007/s00210-012-0748-9 · DOI
- Castro, 2011, Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases, Pharmacol. Res., 64, 551, 10.1016/j.phrs.2011.05.005 · DOI
- Yamada, 2000, ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs, Inflamm. Res., 49, 144, 10.1007/s000110050573 · DOI
- Golub, 1987, A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity, J. Dent. Res., 66, 1310, 10.1177/00220345870660080401 · DOI · Paper page
- Richards, 2011, Antimicrobial and non-antimicrobial tetracyclines in human cancer trials, Pharmacol. Res., 63, 151, 10.1016/j.phrs.2010.10.008 · DOI
- Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
- Bartel, 2009, MicroRNAs: target recognition and regulatory functions, Cell, 136, 215, 10.1016/j.cell.2009.01.002 · DOI · Paper page
- Mishra, 2009, MicroRNAs as a therapeutic target for cardiovascular diseases, J. Cell. Mol. Med., 13, 778, 10.1111/j.1582-4934.2009.00744.x · DOI · Paper page
- Pelouch, 1993, Role of extracellular matrix proteins in heart function, Mol. Cell. Biochem., 129, 101, 10.1007/BF00926359 · DOI · Paper page
- Tyagi, 1997, Proteinases and myocardial extracellular matrix turnover, Mol. Cell. Biochem., 168, 1, 10.1023/A:1006850903242 · DOI
- Tyagi, 1996, Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy, J. Mol. Cell. Cardiol., 28, 1415, 10.1006/jmcc.1996.0132 · DOI
- Ovechkin, 2005, Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice, J. Appl. Physiol., 99, 2398, 10.1152/japplphysiol.00442.2005 · DOI
- Pavlovsky, 1999, X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity, Protein Sci., 8, 1455, 10.1110/ps.8.7.1455 · DOI
- Care, 2007, MicroRNA-133 controls cardiac hypertrophy, Nat. Med., 13, 613, 10.1038/nm1582 · DOI · Paper page
- Matkovich, 2010, MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts, Circ. Res., 106, 166, 10.1161/CIRCRESAHA.109.202176 · DOI · Paper page
- Chavali, 2012, MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes, Biochem. Biophys. Res. Commun., 425, 668, 10.1016/j.bbrc.2012.07.105 · DOI
- Mishra, 2010, Stem cells as a therapeutic target for diabetes, Front. Biosci., 15, 461, 10.2741/3630 · DOI
- Eitan, 2010, Acellular cardiac extracellular matrix as a scaffold for tissue engineering: in vitro cell support, remodeling, and biocompatibility, Tissue Eng. Part C Methods, 16, 671, 10.1089/ten.tec.2009.0111 · DOI · Paper page
- Friehs, 2006, Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis, Basic Res. Cardiol., 101, 204, 10.1007/s00395-005-0581-0 · DOI
- Sang, 1998, Complex role of matrix metalloproteinases in angiogenesis, Cell Res., 8, 171, 10.1038/cr.1998.17 · DOI · Paper page
- Brooks, 1998, Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity, Cell, 92, 391, 10.1016/S0092-8674(00)80931-9 · DOI · Paper page
- Brooks, 1996, Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3, Cell, 85, 683, 10.1016/S0092-8674(00)81235-0 · DOI · Paper page
- Sodha, 2009, Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation, Am. J. Physiol. Heart Circ. Physiol., 296, H428, 10.1152/ajpheart.00283.2008 · DOI
- Laham, 1999, Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial, Circulation, 100, 1865, 10.1161/01.CIR.100.18.1865 · DOI · Paper page
- Rosengart, 1999, Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA, Ann. Surg., 230, 466, 10.1097/00000658-199910000-00002 · DOI · Paper page
- Schumacher, 1998, Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease, Circulation, 97, 645, 10.1161/01.CIR.97.7.645 · DOI · Paper page
- Shiojima, 2005, Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure, J. Clin. Invest., 115, 2108, 10.1172/JCI24682 · DOI · Paper page
- Givvimani, 2011, Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure, J. Appl. Physiol., 110, 1093, 10.1152/japplphysiol.01064.2010 · DOI
- Ducharme, 2000, Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction, J. Clin. Invest., 106, 55, 10.1172/JCI8768 · DOI · Paper page
- Hua, 2012, Relationship between endothelial-to-mesenchymal transition and cardiac fibrosis in acute viral myocarditis, Zhejiang Da Xue Xue Bao Yi Xue Ban, 41, 298
- Kalluri, 2009, The basics of epithelial–mesenchymal transition, J. Clin. Invest., 119, 1420, 10.1172/JCI39104 · DOI · Paper page
- Zeisberg, 2007, Endothelial-to-mesenchymal transition contributes to cardiac fibrosis, Nat. Med., 13, 952, 10.1038/nm1613 · DOI · Paper page
- Yang, 2002, Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy, J. Clin. Invest., 110, 1525, 10.1172/JCI0216219 · DOI · Paper page
- Lefer, 2007, A new gaseous signaling molecule emerges: cardioprotective role of hydrogen sulfide, Proc. Natl. Acad. Sci. U.S.A., 104, 17907, 10.1073/pnas.0709010104 · DOI · Paper page
- Qipshidze, 2012, Hydrogen sulfide mitigates cardiac remodeling during myocardial infarction via improvement of angiogenesis, Int. J. Biol. Sci., 8, 430, 10.7150/ijbs.3632 · DOI
- Lin, 2012, Instructive nanofiber scaffolds with VEGF create a microenvironment for arteriogenesis and cardiac repair, Sci. Transl. Med., 4, 146ra109, 10.1126/scitranslmed.3003841 · DOI · Paper page
Cited by
Tan, Y., Zhang, Z., Zheng, C., Wintergerst, K. A., Keller, B. B., & Cai, L. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0339-2 · Cited by 835
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms
Salvatore, T., Pafundi, P. C., Galiero, R., Albanese, G., Di Martino, A., Caturano, A., Vetrano, E., Rinaldi, L., & Sasso, F. C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.695792 · Cited by 165
Soller, K. J., Yang, J., Veglia, G., & Bowser, M. T. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.738807 · Cited by 20
Metadata
- Authors
- Mishra, P. K., Givvimani, S., Chavali, V., & Tyagi, S. C.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 1832
- Issue
- 12
- Pages
- 2271-2276
- ISSN
- 0925-4439
- Cited by
- 49
- References
- 3
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- Funders
- American Heart Association (11BGIA 7690055)
- National Institute of Health (HL-113281, HL-108621, HL-74185)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.